The change of control of Qidi Pharmaceuticals has been completed, and Hunan Silexian has become the controlling shareholder.

On July 15, 2025, Huateng Pharmaceutical's former controlling shareholder Huateng Science and Technology Services successfully bid for 58,606,962 shares held. On August 6, the relevant property rights were transferred, and the shares were subsequently transferred and registered. The company held an extraordinary general meeting of shareholders in 2025 to elect directors. The board of directors elected Jiang Li as chairman and CEO. Based on adjustments to the equity structure and governance framework, the company's controlling shareholder changed to Hunan Sailing Fantasy, with Jiang Li as the actual controller. As of the announcement date, Hunan Sailing Fantasy held 24.47% of the shares, and Hengyang Hongxiang State-owned Investment Group Co., Ltd. held 19.11%. As of the announcement date, the change in control has been completed, the company's business remains stable, and there have been no significant impacts.